Cell therapy

Slingshot Biosciences Announces $23 Million in Series A Financing

Thursday, July 22, 2021 - 12:15pm

Slingshot Biosciences , a biotechnology company building the worlds first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing.

Key Points: 
  • Slingshot Biosciences , a biotechnology company building the worlds first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing.
  • The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies.
  • Slingshot will also invest heavily in its broader adoptive cell therapy and therapeutics platform with this growth financing.
  • Slingshot Biosciences develops synthetic cells for a range of applications in diagnostics and therapeutics.

Stimulating blood vessel formation with magnets

Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

Grit Biotechnology Completes Series A+ Financing to Accelerate Development of its Tumor Infiltrating Lymphocyte (TIL) Therapy Pipeline

Thursday, July 15, 2021 - 3:00pm

SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing.

Key Points: 
  • SHANGHAI, China, July 15, 2021 (GLOBE NEWSWIRE) -- Grit Bio, a leading cell therapy company developing Tumor Infiltrating Lymphocytes (TIL) therapies, today announced the closing of a Series A+ financing.
  • It is on track to bring the first TIL therapy to solid tumor patients in China.
  • The funds raised will help Grit advance its lead program into the clinic and support the development of its rich preclinical pipeline.
  • Grit Bio is a leading Chinese cell therapy company founded by cell therapy experts from Duke University and University of Southern California in 2019.

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

Wednesday, July 14, 2021 - 12:00pm

The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products.

Key Points: 
  • The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products.
  • At full capacity, the manufacturing center is expected to have the flexibility to produce commercial supply of multiple cell therapy products.
  • All of Nkartas NK current cell therapy candidates are also engineered with a membrane-bound IL15, a proprietary version of a cytokine known for activating NK cell growth, to enhance the persistence and activity of the NK cells.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Monday, July 12, 2021 - 1:00pm

Advancing our first allogeneic CAR-T cell therapy into the clinic represents a major milestone for Caribou, said Rachel Haurwitz, Ph.D., Caribous president and chief executive officer.

Key Points: 
  • Advancing our first allogeneic CAR-T cell therapy into the clinic represents a major milestone for Caribou, said Rachel Haurwitz, Ph.D., Caribous president and chief executive officer.
  • We believe that improving cell persistence is the key to unlocking the full potential of these therapies.
  • This allows us to create sophisticated allogeneic cell therapies with enhanced characteristics to potentially improve their effectiveness and durability of antitumor activity compared to other allogeneic cell therapies.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005106/en/

Global Cell and Gene Therapy Market Report 2021: Opportunities, Strategies, COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com

Monday, July 12, 2021 - 12:26pm

The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Going forward increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure will drive the growth in the cell and gene therapy market.
  • The cell and gene therapy market is segmented by product into cell therapy, and gene therapy.
  • The gene therapy market was the largest segment of the cell and gene therapy market segmented by product, accounting for 72.4% of the total in 2020.

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Friday, July 9, 2021 - 12:00pm

The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.

Key Points: 
  • The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
  • We believe this unique combination will leverage each technologys strengths, while protecting patients against off-target effects of these powerful immunotherapies.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • Forward-looking statements in this press release include the Companys statements regarding its platforms potential to treat patients suffering from acute myeloid leukemia.

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Thursday, July 8, 2021 - 1:00pm

Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vors invisible eHSC transplant platform with one of Janssens bi-specific antibodies in development for acute myeloid leukemia (AML).

Key Points: 
  • Under the terms of the collaboration, Vor Biopharma will investigate the combination of these two technologies into a treatment solution, pairing Vors invisible eHSC transplant platform with one of Janssens bi-specific antibodies in development for acute myeloid leukemia (AML).
  • We believe this unique combination will leverage each technologys strengths, while protecting patients against off-target effects of these powerful immunotherapies.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • Forward-looking statements in this press release include the Companys statements regarding its platforms potential to treat patients suffering from acute myeloid leukemia.

Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Wednesday, June 30, 2021 - 12:12pm

The "Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The cell therapy market consists of sales of cell therapy and related services.
  • The cell therapy market covered in this report is segmented by technique into stem cell therapy; cell vaccine; adoptive cell transfer (ACT); fibroblast cell therapy; chondrocyte cell therapy.
  • The high cost of cell therapy hindered the growth of the cell therapy market.

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Wednesday, June 30, 2021 - 6:00am

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.

Key Points: 
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.